Jun Du
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jun Du has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
Yujie Zhang
Department of Physiology, Nanjing Medical University, Nanjing, Jiangsu 211166, China
15 shared publicationsYueyuan Wang
Department of Physiology, Nanjing Medical University, Nanjing, Jiangsu 211166, China
13 shared publicationsPengxiang Min
Department of Physiology, Nanjing Medical University, Nanjing, Jiangsu 211166, China
11 shared publications- Luo Gu
Department of Physiology, Nanjing Medical University, Nanjing, China
10 shared publications Tianxiang Xia
Department of Physiology, Nanjing Medical University, Nanjing 211166, China
9 shared publications- Yujie Zhang
Department of Physiology, Nanjing Medical University, Nanjing, China
8 shared publications
Latest Publications
- 25 August 2026
- Published by Springer Nature in 3 Biotech
- Vol. 16 (9) , 384
BDE47 exposure in lung adenocarcinoma: prognostic biomarkers, immune dysregulation, and mechanistic insights from toxicogenomic and docking studies
- 25 August 2026
- Published by Springer Nature in 3 Biotech
- Vol. 16 (9) , 384
BDE47 exposure in lung adenocarcinoma: prognostic biomarkers, immune dysregulation, and mechanistic insights from toxicogenomic and docking studies
- Retracted
- 8 February 2026
- Published by Elsevier in Cellular Signalling
- Vol. 142, 112420
The role of FPR3 in remodeling the immune microenvironment and lung metastasis of colon adenocarcinoma
- 8 February 2026
- Published by Elsevier in Cellular Signalling
- Vol. 142, 112420
RetractedThe role of FPR3 in remodeling the immune microenvironment and lung metastasis of colon adenocarcinoma
- 8 December 2025
- Published by Springer Nature in 3 Biotech
- Vol. 16 (1) , 22
Pan-cancer analysis of oncogenic role of vasodilator-stimulated phosphoprotein (VASP) and validation in liver hepatocellular carcinoma
While vasodilator-stimulated phosphoprotein (VASP) is a key cytoskeletal regulatory protein linked to oral squamous cell carcinoma development, its role in other cancers remains unexplored. In this study, we employed the TCGA database, ESTIMATE algorithm, and TIMER to investigate the correlations of VASP with survival outcomes, clinical features, and immune cell infiltration. We also utilized GO, KEGG, and GSEA enrichment analyses to explore its potential functions and constructed a PPI network using STRING and Cytoscape. Our pan-cancer analysis revealed that VASP mRNA was upregulated in ten and downregulated in six tumor types compared to normal tissues. Of particular interest, aberrant VASP expression was significantly associated with the progression and poor prognosis of liver hepatocellular carcinoma (LIHC) and lung adenocarcinoma (LUAD). The level of VASP mRNA showed notable upregulation in LIHC, and its expression was positively correlated with the levels of T-cell exhaustion markers. Univariate and multivariate Cox regression analysis indicated that VASP could serve as an independent diagnostic biomarker for this cancer type. Functional enrichment analysis revealed that VASP participates in several tumor-related processes, such as extracellular matrix degradation and the chemokine signaling pathway. In addition, VASP protein levels were observed to be significantly elevated in LUAD tissues compared to normal controls. VASP knockdown markedly suppressed the migratory capacity of LUAD cells in vitro. In conclusion, the aberrant expression of VASP is associated with poor prognosis in LIHC and LUAD, and VASP could be used as a novel predictive biomarker for LIHC patients.
- 8 December 2025
- Published by Springer Nature in 3 Biotech
- Vol. 16 (1) , 22
Pan-cancer analysis of oncogenic role of vasodilator-stimulated phosphoprotein (VASP) and validation in liver hepatocellular carcinoma
While vasodilator-stimulated phosphoprotein (VASP) is a key cytoskeletal regulatory protein linked to oral squamous cell carcinoma development, its role in other cancers remains unexplored. In this study, we employed the TCGA database, ESTIMATE algorithm, and TIMER to investigate the correlations of VASP with survival outcomes, clinical features, and immune cell infiltration. We also utilized GO, KEGG, and GSEA enrichment analyses to explore its potential functions and constructed a PPI network using STRING and Cytoscape. Our pan-cancer analysis revealed that VASP mRNA was upregulated in ten and downregulated in six tumor types compared to normal tissues. Of particular interest, aberrant VASP expression was significantly associated with the progression and poor prognosis of liver hepatocellular carcinoma (LIHC) and lung adenocarcinoma (LUAD). The level of VASP mRNA showed notable upregulation in LIHC, and its expression was positively correlated with the levels of T-cell exhaustion markers. Univariate and multivariate Cox regression analysis indicated that VASP could serve as an independent diagnostic biomarker for this cancer type. Functional enrichment analysis revealed that VASP participates in several tumor-related processes, such as extracellular matrix degradation and the chemokine signaling pathway. In addition, VASP protein levels were observed to be significantly elevated in LUAD tissues compared to normal controls. VASP knockdown markedly suppressed the migratory capacity of LUAD cells in vitro. In conclusion, the aberrant expression of VASP is associated with poor prognosis in LIHC and LUAD, and VASP could be used as a novel predictive biomarker for LIHC patients.
- Open Access
- 1 July 2025
- Published by Springer Nature in BMC Medical Education
- Vol. 25 (1) , 1-7
Survey on the current status of international students educational management in China
China has become a new hot spot for foreign students in recent years. The reform of educational management is crucial to improving the quality of teaching and supporting student learning; however, there is a lack of comprehensive data documenting the current state of management in medical programs for foreign students in China. This study conducted a survey among international students enrolled on medical and surgical bachelor’s degree programs (MBBS) from Nanjing medical university in China. A total of 67 valid questionnaires were collected in this study, including 30 international and 37 Chinese sophomores. The questionnaires focused on the teaching quality, operation system, as well as the attitude to campus life and communication modes of those students. The international student group’s mean satisfaction with teaching quality was 2.833 ± 0.348 on a five-point scale, much lower than the native students’ mean score of 3.783 ± 0.417 (p < 0.05). Interestingly, although the impact of the international students’ attitude toward course attraction was similar to that recorded for the Chinese students, they were more unsatisfied with the teacher’s level, the delays in understand what the instructor teaches in class, the failure of accept the teacher’s teaching methods, and the insufficient teaching materials that meet students’ needs. Similarly, the international students expressed less satisfaction than the Chinese students with operation system for education (2.700 ± 0.337 vs. 3.388 ± 0.392, p < 0.05). We also noticed that the international students were shown less adapt to study and life in university than their native counterparts (3.833 ± 1.256 vs. 4.378 ± 0.689, p < 0.05). For international students, the main reasons for this could be that there was substantially lower communication with Chinese teachers and take less part in cultural activities. Although the number of international students studying in China were increasing rapidly, international students are less satisfied with medical education management than Chinese students. This study is a microcosm of the current situation of medical education for the international students in China, hoping to improve the quality of their medical education.
- 1 July 2025
- Published by Springer Nature in BMC Medical Education
- Vol. 25 (1) , 1-7
Open AccessSurvey on the current status of international students educational management in China
China has become a new hot spot for foreign students in recent years. The reform of educational management is crucial to improving the quality of teaching and supporting student learning; however, there is a lack of comprehensive data documenting the current state of management in medical programs for foreign students in China. This study conducted a survey among international students enrolled on medical and surgical bachelor’s degree programs (MBBS) from Nanjing medical university in China. A total of 67 valid questionnaires were collected in this study, including 30 international and 37 Chinese sophomores. The questionnaires focused on the teaching quality, operation system, as well as the attitude to campus life and communication modes of those students. The international student group’s mean satisfaction with teaching quality was 2.833 ± 0.348 on a five-point scale, much lower than the native students’ mean score of 3.783 ± 0.417 (p < 0.05). Interestingly, although the impact of the international students’ attitude toward course attraction was similar to that recorded for the Chinese students, they were more unsatisfied with the teacher’s level, the delays in understand what the instructor teaches in class, the failure of accept the teacher’s teaching methods, and the insufficient teaching materials that meet students’ needs. Similarly, the international students expressed less satisfaction than the Chinese students with operation system for education (2.700 ± 0.337 vs. 3.388 ± 0.392, p < 0.05). We also noticed that the international students were shown less adapt to study and life in university than their native counterparts (3.833 ± 1.256 vs. 4.378 ± 0.689, p < 0.05). For international students, the main reasons for this could be that there was substantially lower communication with Chinese teachers and take less part in cultural activities. Although the number of international students studying in China were increasing rapidly, international students are less satisfied with medical education management than Chinese students. This study is a microcosm of the current situation of medical education for the international students in China, hoping to improve the quality of their medical education.
- Open Access
- 1 February 2025
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 14 (2) , 1070-1084
Oncogenic role and prognostic significance of PIMREG in melanoma
Background: Phosphatidylinositol binding clathrin assembly protein interacting mitotic regulator (PIMREG) plays a significant role in metaphase-to-anaphase transition in cell cycle. Its aberrant expression has been reported to be in correlation with the development of several tumors. However, its role in melanoma remains unknown. This study aimed to investigate the diagnostic and prognostic roles of PIMREG in skin cutaneous melanoma (SKCM). Methods: The expression levels of PIMREG were analyzed in SKCM using datasets downloaded from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Gene Expression Omnibus (GEO). The diagnostic accuracy was assessed using the receiver operating characteristic (ROC) curve. PIMREG was correlated to the functional states of SKCM cells using CancerSEA. Additionally, a protein-protein interaction network was constructed using STRING (https://cn.string-db.org), and hub genes were identified using Cytoscape. Enrichment analysis through Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA) was utilized to explore the potential functions of PIMREG. The single-sample GSEA (ssGSEA) method was employed to investigate the correlation between PIMREG expression and the level of immune infiltration in SKCM. Drug sensitivity and resistance were analyzed using GSCALite and Cellminer. Results: The expression of PIMREG was significantly higher in SKCM tissues. Its overexpression correlated with poor survival outcome in melanoma patients. ROC analysis also revealed that PIMREG had high diagnostic potential, with area under the ROC curve (AUC) value of 0.874. Multivariate regression also identified PIMREG could serve as an independent diagnostic indicator for SKCM. Using the web tool of CancerSEA, we demonstrated that PIMREG is involved in cell cycle, DNA repair, DNA damage, epithelial-mesenchymal transition (EMT), invasion, and proliferation. Functional enrichment analysis revealed that PIMREG might be correlated with some biological processes (BPs) and important pathways related to cancer, including Wnt signaling and epidermis development. Conclusions: PIMREG is a promising diagnostic and prognostic biomarker and may be regarded as a possible therapeutic target for SKCM.
- 1 February 2025
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 14 (2) , 1070-1084
Open AccessOncogenic role and prognostic significance of PIMREG in melanoma
Background: Phosphatidylinositol binding clathrin assembly protein interacting mitotic regulator (PIMREG) plays a significant role in metaphase-to-anaphase transition in cell cycle. Its aberrant expression has been reported to be in correlation with the development of several tumors. However, its role in melanoma remains unknown. This study aimed to investigate the diagnostic and prognostic roles of PIMREG in skin cutaneous melanoma (SKCM). Methods: The expression levels of PIMREG were analyzed in SKCM using datasets downloaded from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Gene Expression Omnibus (GEO). The diagnostic accuracy was assessed using the receiver operating characteristic (ROC) curve. PIMREG was correlated to the functional states of SKCM cells using CancerSEA. Additionally, a protein-protein interaction network was constructed using STRING (https://cn.string-db.org), and hub genes were identified using Cytoscape. Enrichment analysis through Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA) was utilized to explore the potential functions of PIMREG. The single-sample GSEA (ssGSEA) method was employed to investigate the correlation between PIMREG expression and the level of immune infiltration in SKCM. Drug sensitivity and resistance were analyzed using GSCALite and Cellminer. Results: The expression of PIMREG was significantly higher in SKCM tissues. Its overexpression correlated with poor survival outcome in melanoma patients. ROC analysis also revealed that PIMREG had high diagnostic potential, with area under the ROC curve (AUC) value of 0.874. Multivariate regression also identified PIMREG could serve as an independent diagnostic indicator for SKCM. Using the web tool of CancerSEA, we demonstrated that PIMREG is involved in cell cycle, DNA repair, DNA damage, epithelial-mesenchymal transition (EMT), invasion, and proliferation. Functional enrichment analysis revealed that PIMREG might be correlated with some biological processes (BPs) and important pathways related to cancer, including Wnt signaling and epidermis development. Conclusions: PIMREG is a promising diagnostic and prognostic biomarker and may be regarded as a possible therapeutic target for SKCM.
- Open Access
- 30 December 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (1) , 518
Comprehensive Analysis of MICALL2 Reveals Its Potential Roles in EGFR Stabilization and Ovarian Cancer Cell Invasion
Molecules interacting with CasL (MICALs) are critical mediators of cell motility that act by cytoskeleton rearrangement. However, the molecular mechanisms underlying the regulation of cancer cell invasion remain elusive. The aim of this study was to investigate the potential role of one member of MICALs, i.e., MICALL2, in the invasion and function of ovarian cancer cells. We showed by bioinformatics analysis that MICALL2 expression was significantly higher in tissues of advanced-stage ovarian cancer and associated with poor overall survival of patients. MICALL2 was strongly correlated with the infiltration of multiple types of immune cells and T-cell exhaustion markers. Moreover, enrichment analyses showed that MICALL2 was involved in the tumor-related matrix degradation pathway. Mechanistically, MMP9 was identified as the target gene of MICALL2 for the regulation of invadopodium formation and SKOV3, HO-8910PM cell invasion. In addition, EGFR–AKT–mTOR signaling was identified as the downstream pathway of MICALL2 in the regulation of MMP9 expression. Furthermore, MICALL2 silencing promoted EGFR degradation; however, this effect was abrogated by treatment with the autophagy inhibitors acadesine and chloroquine diphosphate. Silencing of MICALL2 resulted in a suppressive activity of Rac1 while suppressing Rac1 activation attenuated the pro-EGFR, pro-MMP9, and proinvasive effects induced by the overexpression of MICALL2. Collectively, our results indicated that MICALL2 participated in the process of immune infiltration and invasion by ovarian cancer cells. Moreover, MICALL2 prevented EGFR degradation in a Rac1-dependent manner, consequently leading to EGFR–AKT–mTOR–MMP9 signaling activation and invadopodia-mediated matrix degradation.
- 30 December 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (1) , 518
Open AccessComprehensive Analysis of MICALL2 Reveals Its Potential Roles in EGFR Stabilization and Ovarian Cancer Cell Invasion
Molecules interacting with CasL (MICALs) are critical mediators of cell motility that act by cytoskeleton rearrangement. However, the molecular mechanisms underlying the regulation of cancer cell invasion remain elusive. The aim of this study was to investigate the potential role of one member of MICALs, i.e., MICALL2, in the invasion and function of ovarian cancer cells. We showed by bioinformatics analysis that MICALL2 expression was significantly higher in tissues of advanced-stage ovarian cancer and associated with poor overall survival of patients. MICALL2 was strongly correlated with the infiltration of multiple types of immune cells and T-cell exhaustion markers. Moreover, enrichment analyses showed that MICALL2 was involved in the tumor-related matrix degradation pathway. Mechanistically, MMP9 was identified as the target gene of MICALL2 for the regulation of invadopodium formation and SKOV3, HO-8910PM cell invasion. In addition, EGFR–AKT–mTOR signaling was identified as the downstream pathway of MICALL2 in the regulation of MMP9 expression. Furthermore, MICALL2 silencing promoted EGFR degradation; however, this effect was abrogated by treatment with the autophagy inhibitors acadesine and chloroquine diphosphate. Silencing of MICALL2 resulted in a suppressive activity of Rac1 while suppressing Rac1 activation attenuated the pro-EGFR, pro-MMP9, and proinvasive effects induced by the overexpression of MICALL2. Collectively, our results indicated that MICALL2 participated in the process of immune infiltration and invasion by ovarian cancer cells. Moreover, MICALL2 prevented EGFR degradation in a Rac1-dependent manner, consequently leading to EGFR–AKT–mTOR–MMP9 signaling activation and invadopodia-mediated matrix degradation.
- Open Access
- 2 November 2023
- Published by BMJ
- Vol. 11 (Suppl 1) , A1287
1168 Identification of fully human TCR-mimic antibodies targeting the KRAS G12V/HLA complex generated in HLA-transgenic RenMabTM mice
Background Mutations in the small GTPase protein KRAS drive several cancers, owing to accelerated growth and differentiation phenotypes resulting from altered GDP-GTP exchange and GTP hydrolysis rates. As targeting RAS proteins with traditional drug modalities has proved to be challenging, new therapeutic strategies are needed. Here, we generated and screened TCR-mimic antibody hits targeting the mutant KRAS G12V peptide/HLA complex, as the majority of KRAS mutations occur at this residue.1 Methods HLA-transgenic RenMice™ were immunized with KRAS G12V/HLA-A0301 or KRAS G12V/HLA-A1101 peptide-MHC (pMHC) complexes. The specificity of antibody hits recovered from the mice, as well as a positive control antibody previously described,2 was tested on HLA-A overexpressing cells in the context of various KRAS peptides by flow cytometry. Positive hits were assessed for heavy and light chain germline gene usage and CDR3 length, and KD values were measured. To assess specificity of the antibodies, binding of two candidate antibody hits to other peptide and/or HLA complexes were tested. Alanine scanning substitutions of the KRAS G12V peptide were also performed to identify the residues critical for TCR-mimic antibody recognition. Killing of HLA-A0301+ cells with KRAS G12V or wildtype KRAS by TCR-mimic antibody candidate 2 conjugated to a CD3-targeting antibody was subsequently measured (by LDH activity) in the context of human T cells. Results We identified TCR-mimic antibodies with specificity for KRAS G12V residues 7–16 complexed with HLA-A0301 or HLA-A1101 by flow cytometry. KRAS G12V/HLA-A1101 and KRAS G12V/HLA-A0301 antibody hits exhibited varying degrees of germline gene diversity and CDR3 length, with the majority of KRAS G12V/HLA-A0301 antibodies exhibiting higher affinity than the positive control. KRAS G12V/HLA-A0301 antibodies specifically bound HLA-A0301 overexpressing cells pulsed with KRAS G12V decamer peptide in a dose-dependent manner, but did not bind KRAS G12C, G12D, WT peptide or unpulsed controls. Furthermore, KRAS G12V/HLA-A0301 antibodies did not bind HLA-A1101 overexpressing cells loaded with KRAS mutant or WT peptides, or HLA-A0301 overexpressing cells loaded with off-target peptide. Alanine substitutions revealed that residue V6 of KRAS G12V was required for antibody binding. Cytotoxicity assays demonstrate specificity of KRAS G12V/HLA-A0301 antibody for KRAS G12V+/HLA-A0301+ cells. Conclusions Using our novel fully human HLA-transgenic RenMice, we have successfully generated and screened TCR-mimic antibodies specific for KRAS G12V/HLA-A0301 pMHC or KRAS G12V/HLA-A1101 pMHC complexes for further preclinical investigation. References Moore AR, Rosenberg SC, McCormick F, et al. RAS-targeted therapies: is the undruggable drugged?. Nat Rev Drug Discov 2020;19:902. https://doi.org/10.1038/s41573–020-0089–1 Douglass J, Hsiue EH, Mog BJ, Hwang MS, DiNapoli SR, Pearlman AH, Miller MS, Wright KM, Azurmendi PA, Wang Q, Paul S, Schaefer A, Skora AD, Molin MD, Konig MF, Liu Q, Watson E, Li Y, Murphy MB, Pardoll DM, Bettegowda C, Papadopoulos N, Gabelli SB, Kinzler KW, Vogelstein B, Zhou S. Bispecific antibodies targeting mutant RAS neoantigens. Sci Immunol. 2021 Mar 1;6(57):eabd5515. doi: 10.1126/sciimmunol.abd5515. PMID: 33649101; PMCID: PMC8141259. Ethics Approval All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Biocytogen Beijing Co., Ltd.
- 2 November 2023
- Published by BMJ
- Vol. 11 (Suppl 1) , A1287
Open Access1168 Identification of fully human TCR-mimic antibodies targeting the KRAS G12V/HLA complex generated in HLA-transgenic RenMabTM mice
Background Mutations in the small GTPase protein KRAS drive several cancers, owing to accelerated growth and differentiation phenotypes resulting from altered GDP-GTP exchange and GTP hydrolysis rates. As targeting RAS proteins with traditional drug modalities has proved to be challenging, new therapeutic strategies are needed. Here, we generated and screened TCR-mimic antibody hits targeting the mutant KRAS G12V peptide/HLA complex, as the majority of KRAS mutations occur at this residue.1 Methods HLA-transgenic RenMice™ were immunized with KRAS G12V/HLA-A0301 or KRAS G12V/HLA-A1101 peptide-MHC (pMHC) complexes. The specificity of antibody hits recovered from the mice, as well as a positive control antibody previously described,2 was tested on HLA-A overexpressing cells in the context of various KRAS peptides by flow cytometry. Positive hits were assessed for heavy and light chain germline gene usage and CDR3 length, and KD values were measured. To assess specificity of the antibodies, binding of two candidate antibody hits to other peptide and/or HLA complexes were tested. Alanine scanning substitutions of the KRAS G12V peptide were also performed to identify the residues critical for TCR-mimic antibody recognition. Killing of HLA-A0301+ cells with KRAS G12V or wildtype KRAS by TCR-mimic antibody candidate 2 conjugated to a CD3-targeting antibody was subsequently measured (by LDH activity) in the context of human T cells. Results We identified TCR-mimic antibodies with specificity for KRAS G12V residues 7–16 complexed with HLA-A0301 or HLA-A1101 by flow cytometry. KRAS G12V/HLA-A1101 and KRAS G12V/HLA-A0301 antibody hits exhibited varying degrees of germline gene diversity and CDR3 length, with the majority of KRAS G12V/HLA-A0301 antibodies exhibiting higher affinity than the positive control. KRAS G12V/HLA-A0301 antibodies specifically bound HLA-A0301 overexpressing cells pulsed with KRAS G12V decamer peptide in a dose-dependent manner, but did not bind KRAS G12C, G12D, WT peptide or unpulsed controls. Furthermore, KRAS G12V/HLA-A0301 antibodies did not bind HLA-A1101 overexpressing cells loaded with KRAS mutant or WT peptides, or HLA-A0301 overexpressing cells loaded with off-target peptide. Alanine substitutions revealed that residue V6 of KRAS G12V was required for antibody binding. Cytotoxicity assays demonstrate specificity of KRAS G12V/HLA-A0301 antibody for KRAS G12V+/HLA-A0301+ cells. Conclusions Using our novel fully human HLA-transgenic RenMice, we have successfully generated and screened TCR-mimic antibodies specific for KRAS G12V/HLA-A0301 pMHC or KRAS G12V/HLA-A1101 pMHC complexes for further preclinical investigation. References Moore AR, Rosenberg SC, McCormick F, et al. RAS-targeted therapies: is the undruggable drugged?. Nat Rev Drug Discov 2020;19:902. https://doi.org/10.1038/s41573–020-0089–1 Douglass J, Hsiue EH, Mog BJ, Hwang MS, DiNapoli SR, Pearlman AH, Miller MS, Wright KM, Azurmendi PA, Wang Q, Paul S, Schaefer A, Skora AD, Molin MD, Konig MF, Liu Q, Watson E, Li Y, Murphy MB, Pardoll DM, Bettegowda C, Papadopoulos N, Gabelli SB, Kinzler KW, Vogelstein B, Zhou S. Bispecific antibodies targeting mutant RAS neoantigens. Sci Immunol. 2021 Mar 1;6(57):eabd5515. doi: 10.1126/sciimmunol.abd5515. PMID: 33649101; PMCID: PMC8141259. Ethics Approval All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Biocytogen Beijing Co., Ltd.
- Open Access
- 1 September 2023
- Published by Springer Nature in Research Square
MICAL1 stability by PlexinA1 promotes gastric cancer cell migration
Background For metastasis to proceed, tumor cells must become mobile by modulating their cytoskeleton. MICAL1 is known as an actin cytoskeleton regulator, but the mechanisms by which it drives cancer cell migration are still unclear. Methods Immunohistochemistry assays and western blotting were used to detect the expression levels of MICAL1 in gastric cancer tissues and cells. Immunoprecipitation and immunofluorescence staining were used to detect the interactions of proteins. Wound-healing and transwell assays were performed to demonstrate the migratory function of MICAL1 in gastric cancer cells. In addition, qPCR, bioinformatics analysis, pulldown assay, ROS detection as well as western blotting were conducted to verify the mechanism of MICAL1 in gastric cancer cell migration. Results Analysis of gastric cancer tissues revealed that MICAL1 are elevated in gastric cancer tissues compared with non-tumor tissues and that its high expression is predictive of poor survival. PlexinA1 and MICAL1 were directly interact with each other. Specific inhibition of PlexinA1 accelerated MICAL1 ubiquitination and proteasome-based degradation. Furthermore, PlexinA1 positively regulates MICAL1 expression via Rac1 activation and following ROS production. Functional studies confirmed that PlexinA1 and MICAL1 facilitated gastric cancer cell migration via promoting vimentin expression. Conclusions These results indicate that PlexinA1 is a key regulator of MICAL1 stability via a Rac1/ROS dependent manner, and MICAL1 stability may be involved in promoting vimentin expression and gastric cancer cell migration.
- 1 September 2023
- Published by Springer Nature in Research Square
Open AccessMICAL1 stability by PlexinA1 promotes gastric cancer cell migration
Background For metastasis to proceed, tumor cells must become mobile by modulating their cytoskeleton. MICAL1 is known as an actin cytoskeleton regulator, but the mechanisms by which it drives cancer cell migration are still unclear. Methods Immunohistochemistry assays and western blotting were used to detect the expression levels of MICAL1 in gastric cancer tissues and cells. Immunoprecipitation and immunofluorescence staining were used to detect the interactions of proteins. Wound-healing and transwell assays were performed to demonstrate the migratory function of MICAL1 in gastric cancer cells. In addition, qPCR, bioinformatics analysis, pulldown assay, ROS detection as well as western blotting were conducted to verify the mechanism of MICAL1 in gastric cancer cell migration. Results Analysis of gastric cancer tissues revealed that MICAL1 are elevated in gastric cancer tissues compared with non-tumor tissues and that its high expression is predictive of poor survival. PlexinA1 and MICAL1 were directly interact with each other. Specific inhibition of PlexinA1 accelerated MICAL1 ubiquitination and proteasome-based degradation. Furthermore, PlexinA1 positively regulates MICAL1 expression via Rac1 activation and following ROS production. Functional studies confirmed that PlexinA1 and MICAL1 facilitated gastric cancer cell migration via promoting vimentin expression. Conclusions These results indicate that PlexinA1 is a key regulator of MICAL1 stability via a Rac1/ROS dependent manner, and MICAL1 stability may be involved in promoting vimentin expression and gastric cancer cell migration.